title: Effects of pramlintide in patients with type 2 diabetes mellitus: an analysis using daily insulin dose tertiles.
abstract: OBJECTIVE
  The purpose of the analysis was to investigate if the efficacy and tolerability of 6 months of pramlintide therapy in patients with type 2 diabetes mellitus (T2DM) differed with increasing levels of concomitant insulin doses, using data from 3 previously described clinical trials.
  
  
  METHODS
  In this post hoc analysis, data from 2 pooled, placebo-controlled pivotal trials and 1 clinical practice trial were evaluated by baseline insulin use tertile in patients with T2DM.
  
  
  RESULTS
  In the pivotal trials, both glycated hemoglobin (A1C) and body weight decreased similarly across tertiles with pramlintide. A1C decreased slightly and body weight remained relatively unchanged across tertiles with placebo. Similarly, in the clinical practice trial, pramlintide was associated with decreases in A1C, body weight, and total daily insulin use across the tertiles. Overall, the most common adverse events were gastrointestinal in nature, and the rate of severe hypoglycemia was low.
  
  
  CONCLUSIONS
  These results suggest that pramlintide therapy was associated with improved A1C and decreased body weight, with a low rate of severe hypoglycemia, among patients with T2DM, regardless of baseline insulin use.
authors.affiliation: AstraZeneca, San Diego, California.
authors.forename: Kathrin
authors.initials: K
authors.lastname: Herrmann
authors.affiliation: Bristol-Myers Squibb/AstraZeneca, San Diego, California.
authors.forename: Kevin
authors.initials: K
authors.lastname: Shan
authors.affiliation: Bristol-Myers Squibb/AstraZeneca, San Diego, California.
authors.forename: Steven C
authors.initials: SC
authors.lastname: Brunell
authors.affiliation: Bristol-Myers Squibb/AstraZeneca, San Diego, California.
authors.forename: Steve
authors.initials: S
authors.lastname: Chen
mesh_terms: D000682:Amyloid; D001786:Blood Glucose; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D006442:Glycated Hemoglobin; D006801:Humans; D007003:Hypoglycemia; D007004:Hypoglycemic Agents; D007328:Insulin; D058228:Islet Amyloid Polypeptide / Q000627:therapeutic use*
chemical_list: D000682:Amyloid; D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; D058228:Islet Amyloid Polypeptide; C105254:pramlintide